{"name":"Beijing Continent Pharmaceutical Co, Ltd.","slug":"beijing-continent-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"beijingcontinent.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"F230 tablets","genericName":"F230 tablets","slug":"f230-tablets","indication":"Other","status":"phase_1"},{"name":"Hydronidone (Placebo Group)","genericName":"Hydronidone (Placebo Group)","slug":"hydronidone-placebo-group","indication":"Other","status":"phase_3"},{"name":"The placebo capsules","genericName":"The placebo capsules","slug":"the-placebo-capsules","indication":"Control in clinical trials","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Hydronidone (270mg)","genericName":"Hydronidone (270mg)","slug":"hydronidone-270mg","indication":"Inflammatory and autoimmune disorders (specific indication under phase 3 evaluation not publicly detailed)","status":"phase_3"},{"name":"Hydronidone capsules","genericName":"Hydronidone capsules","slug":"hydronidone-capsules","indication":"Inflammatory and autoimmune disorders (specific indications in phase 3 development unknown)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"F573 for injection","genericName":"F573 for injection","slug":"f573-for-injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Pirfenidone Capsules（600mg）","genericName":"Pirfenidone Capsules（600mg）","slug":"pirfenidone-capsules-600mg","indication":"Idiopathic pulmonary fibrosis","status":"phase_2"}]}],"pipeline":[{"name":"F230 tablets","genericName":"F230 tablets","slug":"f230-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"F573 for injection","genericName":"F573 for injection","slug":"f573-for-injection","phase":"phase_2","mechanism":"F573 for injection is a monoclonal antibody targeting the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Hydronidone (270mg)","genericName":"Hydronidone (270mg)","slug":"hydronidone-270mg","phase":"phase_3","mechanism":"Hydronidone is a corticosteroid that reduces inflammation and suppresses immune responses by binding to glucocorticoid receptors.","indications":["Inflammatory and autoimmune disorders (specific indication under phase 3 evaluation not publicly detailed)"],"catalyst":""},{"name":"Hydronidone (Placebo Group)","genericName":"Hydronidone (Placebo Group)","slug":"hydronidone-placebo-group","phase":"phase_3","mechanism":"Hydronidone is a placebo control agent with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Hydronidone capsules","genericName":"Hydronidone capsules","slug":"hydronidone-capsules","phase":"phase_3","mechanism":"Hydronidone is a corticosteroid that reduces inflammation and suppresses immune responses by binding to glucocorticoid receptors.","indications":["Inflammatory and autoimmune disorders (specific indications in phase 3 development unknown)"],"catalyst":""},{"name":"Pirfenidone Capsules（600mg）","genericName":"Pirfenidone Capsules（600mg）","slug":"pirfenidone-capsules-600mg","phase":"phase_2","mechanism":"Antifibrotic agent","indications":["Idiopathic pulmonary fibrosis"],"catalyst":""},{"name":"The placebo capsules","genericName":"The placebo capsules","slug":"the-placebo-capsules","phase":"phase_3","mechanism":"The placebo capsules are inert substances used as a control in clinical trials.","indications":["Control in clinical trials"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOV2RXUmsxUHJhNWNLMFRJOER5eE5kT1ljSDliX2tzNHZ6MmRqazdLdVUzRDZMWWpUNE1pS2dxM2lZUEtjeW5XQTkzdmtLcVdpYW9qTmJlQVR1cV84enBvazV6ZjJNTDVRVGVBbUlNcVdYZ2hPXzhnS0FPM1BEem9pZlU2ckRjVkJKSEV0ZXZDbUk4MjZ2YlVJ?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Liver Fibrosis Clinical Trial Pipeline Accelerates as 50+ - openPR.com","headline":"Liver Fibrosis Clinical Trial Pipeline Accelerates as 50+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxOVE90MGtHc0xEdnVFZlRNVHJLZjJ2M2VXUlJsSDV1SVBxSDh0WmprYTlya2k0Ym5PSEx0NmF1NGtSUUxSQjV4bmFLWVBLN0g4RGpVdmlvQjNMZGI0b2dQRmhUYl83MENKQjdDVXljZUlDVXdYTWJHeXJ1TmxtbzlSTkx4R0FEM2NpWVgtenNWS3gtRGZEcWFtNGxoS2RnczVJOHNObVRSdDY2Ym4wZklDZ0djUFV4QU83UXVweGJrTzE1YmNOZnB1Nk51cmQ5allJeElMaF9JMEZfeHJiR3lsWFQwTHEtVTdpNkJmZjJ2UDYyS3BhcHFGa3FYNjFTeUZIcWc?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Systemic Sclerosis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"Systemic Sclerosis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQbU1uRl81M1B0UEl4Q0JOcGVaekFZQjRkbFp3R1FYdy1HSm51WlppTWNRX1NyRVQtcXNZQzdTaWZRbHQzZm1OVnpOX3g3MHdodDlNdm9aOHNyQUlPWjZrTUQ1Z19DMWtheFd6QTdTT1hLeGQ3TlhMNTE2YVROaU82c3pzMk5aUUxONGw4eGFkN2lvZWh6ZWR6VEtYOUh2VlE?oc=5","date":"2026-03-02","type":"deal","source":"Fierce Biotech","summary":"Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout - Fierce Biotech","headline":"Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOQ1VHaHQxSGJLT2tBS29MX0xpQ1Ytdkc0R2FPT2s5cnNDNnB2Q1lXR2dZSm1neVhPVmJYZGJ6bXlhNENPWDNDSjZCUURRZmR0aGlKb0FwLTJWcWRCSEJEVFBZLWlPNF9nZktkRFpaY3ZiTmFFQTkzRXYzZkU3Yy04N2V5Uk9YZE9POVp4bzFZU3ZPdzBWRm1ydUR2aGlqTDdILVBHRmRwSjhGVGVWM2xhNGFhWTR3bkE?oc=5","date":"2025-04-24","type":"pipeline","source":"Pharmacy Times","summary":"Investigators Anticipate Hydronidone Will Be Beneficial for Liver Fibrosis in CHB - Pharmacy Times","headline":"Investigators Anticipate Hydronidone Will Be Beneficial for Liver Fibrosis in CHB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNeVJfaDI0Ui1CNEdnejY3VXNtQWRLX2xSa3l1VWJMY2pmWTBrWEdvSE05bmlsMHhHRGZtNzYxRjF4cnpDSWtrX184SGFhS3BYR1Qtd2lTUDJ1RlBfdXpfNUd0YmVuUGIybXZoZ0MyWTMya0F5Q09YVHVqWC1SMnJUWVFGaVg0VXlsMERVS3pWdmxLSkhpTjlxTF92bzJEaFpFUTBmZzlrUUtYQjdMalpPZGkyVTVLX3RaM3c?oc=5","date":"2025-03-27","type":"trial","source":"Stock Titan","summary":"Major Breakthrough: New Phase 3 Trial Targets Chronic Hepatitis B Liver Fibrosis Treatment - Stock Titan","headline":"Major Breakthrough: New Phase 3 Trial Targets Chronic Hepatitis B Liver Fibrosis Treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOX2xMdVlLZXJlQjY4bWVCQnBoWGdoa0JPNE1mVG5KbjNuYTZabnJoVG9yWnRaU1RRM2tMZGFHMEF1Z0NuMXpqa3hfNUtXelNaWXNtOW9WSWt1cU02RXlVemwtR2JVVEVjcTUtNVR6aXlsM3ByU0hjUktBeUtiS1hGV0FOY2VrY3Z2VXlHVHZLOUxoMjlSYWU4TjRNX2JrOTBBSjFfeUE5Z0wxcEV3SDZZZ1J2N0JwRzZubTJ0SklzbFlWVThhbC16ZFVUT2J6UTRySmxmSnRwVQ?oc=5","date":"2025-03-05","type":"pipeline","source":"PR Newswire","summary":"Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight - PR Newswire","headline":"Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbUxubkxJRnpsRVRFN1JPMzU5WmdvTXZnUVUxV2doNWs5UVc1LVpsWjRuT2tCMTJtSmFSZ05mc283RGtvc2Ywcm1DZ0NfWGx5WVB6Q1RtWDlLV21CTGxNNDJac3ZuN2VjS1BzdDFUMVZTMXhyQ2VCdXhtZTRpS01Wc09tNTFISGpzSGZjaWlYa2w0emIwMTZQQmJLM19Uek5wVTk5S0VaUjdQVVE?oc=5","date":"2022-03-16","type":"pipeline","source":"富途牛牛","summary":"Cantini Pharmaceuticals submitted a listing to the Hong Kong Stock Exchange to lay out the field of organ fibrosis - 富途牛牛","headline":"Cantini Pharmaceuticals submitted a listing to the Hong Kong Stock Exchange to lay out the field of organ fibrosis - 富途牛","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_1":1,"phase_2":2,"phase_3":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}